CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial.
Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CD8+ T 细胞、PD-L1+细胞、CD68+巨噬细胞和 PANCK-PD-L1+免疫细胞在浸润边缘的多参数免疫分析可能有助于识别可能从抗 PD-1 联合治疗中获益的宫颈癌患者。
检查点免疫治疗是晚期宫颈癌的一种有前景的治疗选择。为了帮助选择适合该治疗的患者，我们确定了抗PD-1联合治疗反应的潜在预测因素。
我们通过多光谱成像技术，对来自先前试验队列中37例晚期宫颈癌患者的组织切片，在肿瘤浸润边缘（IM）同时表征了CD8+、FoxP3+、PD-L1+、CD68+、CD31+、PANCK+以及PANCK-PD-L1+细胞。比较了应答组与非应答组之间各细胞密度及细胞间拓扑结构，并评估了它们在临床应答和生存方面的预测价值。
CD8 + T细胞、PD-L1 +细胞和PANCK - PD-L1 +免疫细胞在应答者中IM处的密度高于非应答者（分别为P = 0.022、0.0094和0.049）。IM处CD8 + T细胞密度较高与无进展生存期（PFS）延长相关（P = 0.031）。非应答者组中CD68 + /CD8 +细胞比值较高（P = 0.003），且与较差的PFS相关（P = 0.016）。在距离PANCK +肿瘤细胞20、30和45 µm范围内，PANCK - PD-L1 +免疫细胞密度较高与更好的临床应答相关（分别为P = 0.017、0.017和0.02）。
Checkpoint immunotherapy is a promising treatment option for advanced cervical cancer. To aid in selecting patients for this treatment, we identified potential predictors of the response to anti-PD-1 combination therapy.
We simultaneously characterized CD8 + , FoxP3 + , PD-L1 + , CD68 + , CD31 + , PANCK + , and PANCK - PD-L1 + cells at the invasive margin (IM) of tumor by multispectral imaging of tissue sections from 37 patients with advanced cervical cancer in our previous trial cohort. The densities of each cell and cell-to-cell topography were compared between the responder and non-responder groups and evaluated for their predictive value in clinical response and survival.
CD8 + T cells, PD-L1 + cells, and PANCK - PD-L1 + immune cells showed higher densities at the IM in the responders than in the non-responders (P = 0.022, 0.0094, and 0.049, respectively). A higher density of CD8 + T cells at the IM was related to prolonged progression-free survival (PFS; P = 0.031). A higher ratio of CD68 + /CD8 + cells was found in the non-responder group (P = 0.003) and related to poor PFS (P = 0.016). A higher density of PANCK - PD-L1 + immune cells within 20, 30, and 45 µm of PANCK + tumor cells was correlated with better clinical response (P = 0.017, 0.017, and 0.02, respectively).
Multiparametric immune profiling of CD8 + T cells, PD-L1 + cells, CD68 + macrophages and PANCK - PD-L1 + immune cells at the invasive margin may help identify patients with cervical cancer who may benefit from anti-PD-1 combination therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials. gov identifier: NCT03816553, January 25, 2019.
MEMBER ACCOUNT
登录成功会直接打开下一页。
